Wyeth Pharmaceuticals started a process of re-engineering its drug discovery operations five years ago with the goal of improving its performance and identifying more clinical candidates. According to the firm, the process was a major success, and it has the numbers to back up that claim. Dr. Robert Ruffolo, president of research and development for Wyeth Pharmaceuticals, gave a talk last week at the PharmaDiscovery Conference in Washington, DC, describing the organizational changes and ways the firm maximized its use of drug discovery tools to improve productivity.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.